Introduction
The 510(k) submission process is a critical regulatory mechanism employed by the FDA to oversee the introduction of moderate-risk medical devices into the U.S. market. This process involves affirming that a new device is “substantially equivalent” to a legally marketed device, known as a predicate device. The evaluation includes comparisons in intended use, technological characteristics, and safety and effectiveness parameters.
Understanding the specific classification of a medical device is crucial, as it determines the appropriate regulatory pathway. Recent scrutiny of the 510(k) process has emphasized the importance of thorough comparative analyses and evaluation of Summaries of Safety and Effectiveness (SSEs). Staying informed on FDA guidelines and developments is essential for regulatory professionals to ensure comprehensive compliance.
This article provides a step-by-step guide, eligibility criteria, key components of a submission, and insights into the substantial equivalence evaluation. By following best practices and engaging with the FDA, manufacturers can navigate the complexities of the 510(k) process and work towards achieving FDA clearance for their medical devices.
What is the 510(k) Pathway?
The is a pivotal regulatory mechanism employed by the FDA to oversee the introduction of moderate-risk into the U.S. market. The crux of this process is to affirm that a new device is “” to a legally marketed device, known as a predicate device. This means that the new device must be as safe and effective as an existing device that has already been cleared by the FDA. This assessment of equivalence includes comparisons in intended use, technological characteristics, and safety and effectiveness parameters.
Understanding the is crucial, as the FDA categorizes devices into three distinct levels based on the associated patient risk. Once classified, the manufacturer must navigate through the appropriate regulatory pathway, whether it’s the , Pre-Market Approval (PMA), or the De Novo process. A device must be , Approved, or Granted authorization through the De Novo process before it can be legally marketed in the U.S. It’s imperative to grasp the nuances between these terms, as they are not interchangeable and carry significant regulatory implications.
In light of recent conversations and documentaries, such as ‘The Bleeding Edge’ released in 2018, there has been increased scrutiny of the due to concerns that not all devices undergo stringent clinical trials before approval. This has highlighted the importance of thorough comparative analysis and the evaluation of Summaries of Safety and Effectiveness (SSEs) during the . Engaging deeply with the subject device, its users, and the instructions for use is just as important as understanding the competitive landscape and identifying potential predicate devices through extensive research, including clinical studies and market comparisons.
As the FDA continues to update its guidelines and advisory committees on matters such as the Breakthrough Devices Program and digital health technologies, staying informed on these developments is essential for regulatory professionals. They must also ensure comprehensive responses to any FDA communications, such as Warning Letters, and provide thorough reasoning and documentation when addressing potential violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
Eligibility Criteria for 510(k) Clearance
Navigating the by the FDA requires a comprehensive understanding of the device’s classification, intended use, and technological traits. The FDA categorizes into three distinct classifications based on the level of risk to patients. Prior to marketing a device in the United States, one must adhere to the appropriate : , Premarket Approval (PMA), or the De Novo process, following which the device may be .
For a successful 510(k) submission, it’s crucial to conduct a thorough investigation of the device in question. This involves gaining insights into the device’s users such as clinicians and patients, as well as its instructions for use, inclusive of any warnings. Collaboration with marketing teams can provide a broader view of the competitive landscape, allowing for the identification of potential predicate devices that share similar intended uses and technological characteristics. Creating a comparative table is a recommended step in this process.
serve as a valuable resource for understanding current thinking on various topics, although they do not impose legally enforceable duties. Instead, they offer recommendations unless they reference specific regulatory or statutory requirements. When preparing a submission, it’s beneficial to consult the , which presents regulations in a structured and user-friendly format.
Staying informed about FDA activities is also critical. The agency, part of the U.S. Department of Health and Human Services, is tasked with ensuring public health by overseeing the safety, efficacy, and security of , among other responsibilities. Recognizing the nuances between FDA terms such as ‘Registered,’ ‘Cleared,’ ‘Approved,’ and ‘Granted’ is essential for regulatory professionals and contributes to a clear understanding of the regulatory environment. Moreover, special designations like ‘orphan-drug’ have specific implications, including exclusive approval under certain conditions which prevent subsequent sponsor approval for the same drug and indication for seven years, barring exceptions outlined by law.
Key Components of a 510(k) Submission
To navigate the effectively, it is crucial to possess a profound understanding of the medical device in question, including its intended use, user base—ranging from clinicians to patients—and the specific instructions for use, which encompass all necessary warnings and precautions. Additionally, it is essential to collaborate with Marketing departments to comprehend the competitive landscape, as this will aid in identifying potential that share a similar intended use and technological characteristics. A comparative table should be initiated to meticulously document these parallels.
A thorough review of research literature, , and marketing materials such as websites, brochures, and labeling is vital in establishing the predicate device. It is advised to then delve into the Summaries of Safety and Effectiveness Data (SSED) accessible through the FDA’s 510(k) database, to discern the similarities and differences between the subject device and the predicate.
The submission’s success hinges on the comprehensive assembly of its components: the cover letter, a detailed device description, proposed labeling, performance data, and a comparison to the predicate device. Each element is integral to substantiating the of the device. Prospective applicants are reminded to adhere to the and familiarize themselves with the submission process to enhance the likelihood of a favorable review for substantial equivalence.
Moreover, it is imperative to be cognizant of the submitted to the FDA. Comments, including attachments, submitted electronically become part of the public docket and are accessible to everyone. To safeguard sensitive information, it is incumbent upon the submitter to avoid including confidential data within the comments or opt for a written submission with .
An understanding of the broader context, such as the implications of safety standards and the potential economic and reputational repercussions, is also beneficial. This awareness can guide strategic decisions that balance regulatory compliance with public interest considerations.
Step-by-Step Guide to Preparing a 510(k) Submission
is a meticulous process that demands a strategic approach and thorough . To ensure a successful submission, start by identifying a that shares similar characteristics and intended use with your device. A thorough comparison to this predicate is foundational to your submission.
Next, determine the appropriate device classification by consulting the FDA’s classification regulations. This classification will dictate the level of regulatory control and the requirements for your submission.
Conducting comprehensive testing on your device is crucial to collect performance data and demonstrate compliance with the relevant standards. This data will form a pivotal part of your submission, supporting your claims of safety and effectiveness.
The preparation of submission documentation is a multi-faceted task. It involves compiling a cover letter, detailed device description, labeling information, and all test data. Accuracy and clarity in this documentation are paramount, as it will be scrutinized by the FDA during their review process.
Furthermore, complete the necessary FDA forms with precision, including Form 3514 and Form 3601. Accuracy in these forms is essential to avoid any delays in the review process.
Finally, to the FDA, ensuring all components are complete and well-organized. This will facilitate a smoother review process and increase the likelihood of a favorable outcome. For additional guidance, refer to the FDA’s instructions for submitting comments and ensure your submission is devoid of any confidential information that should not be made public.
By following these steps diligently, you will be well-equipped to navigate the process and work towards achieving FDA clearance for your .
Comparing Your Device to a Predicate Device
The is a pivotal step for medical device manufacturers seeking market clearance in the United States. A critical component of this process is the comparison of the new device to an existing, legally marketed device known as the predicate. This involves a thorough analysis of intended use, technological characteristics, and performance data. The goal is to demonstrate to the FDA, affirming that the new device is as safe and effective as the predicate.
To begin this intricate comparison, one must first ensure a comprehensive understanding of the subject device, its users, and its instructions for use, which may include any warnings or cautions. The next phase involves identifying a suitable . This requires an extensive review of competitor devices through research literature, clinical studies, and marketing materials to ascertain a device with the same intended use and similar technological attributes.
Once a potential predicate is identified, it’s imperative to create a comparative table that outlines the similarities and differences in detail. Reading the Summaries of Safety and Effectiveness Data (Seeds) available in the FDA’s 510(k) database can illuminate critical aspects of the , guiding the comparative analysis.
The FDA’s modernization efforts for the , including public feedback on the use of older predicates, have culminated in a set of best practices outlined in draft guidance issued on September 7, 2023. These best practices emphasize the importance of selecting a predicate that not only has the same intended use but also possesses technological characteristics that do not introduce new safety and effectiveness questions.
In light of these guidelines, it is evident that the selection of a is not a mere formality but a strategic decision that can significantly impact the review process. The FDA’s commitment to ensuring public safety while fostering innovation is reflected in their rigorous evaluation of 510(k) submissions, which often includes non-clinical testing and may require in certain scenarios.
Ultimately, the is a nuanced task that demands careful attention to detail and adherence to . It is an essential step in bringing new medical devices to the market that are both innovative and secure for public use.
Substantial Equivalence Evaluation
The process of assessing is a pivotal aspect of the , requiring a meticulous comparison of the new to a legally marketed predecessor, known as the . During this evaluation, the FDA scrutinizes various elements such as the intended use, technological attributes, and overall performance of the device to ascertain its equivalence. It’s not merely a matter of checking off similarities; the FDA places emphasis on both the of the device in context to the predicate. For instance, even if there are differences in technological characteristics, they should not raise new questions of safety or effectiveness. This evaluation is not conducted in isolation; public comments and feedback play a role in the decision-making process, reflecting the FDA’s commitment to transparency and stakeholder engagement. As such, stakeholders are advised to provide feedback while ensuring the confidentiality of sensitive information. The outcome of this comprehensive evaluation has a significant impact on whether the FDA will grant , which is essential for the device to enter the U.S. market. The FDA’s guidance on this matter, while non-binding, offers insight into current thinking and recommended practices for a successful submission. In the ever-evolving landscape of regulation, staying abreast of such guidelines is crucial for manufacturers aiming to navigate the 510(k) process effectively.
FDA Review Process and Timeline
The by the FDA is a pivotal step in bringing s to the U.S. market, ensuring they meet safety and effectiveness standards. This evaluation process scrutinizes the device against a predicate, a previously cleared device with similar characteristics, which streamlines the . Although the average review period extends over several months, the timeline can fluctuate depending on the device’s complexity and the submission’s comprehensiveness. During this phase, manufacturers must be vigilant and responsive, as the FDA may necessitate supplementary information to address specific concerns.
The depth of the review is contingent on the risk category of the device: , which include critical life-sustaining equipment like pacemakers, undergo a more stringent review due to their significant role in patient care. This meticulous process is indicative of the FDA’s commitment to public health, as seen in their recent initiatives to enhance clarity and transparency in direct-to-consumer drug advertisements, emphasizing the presentation of information in a consumer-friendly manner.
Post-clearance, the journey of a continues as other stakeholders, including payors and healthcare providers, undertake their own assessments to determine coverage and reimbursement. The data that satisfied may not always align with the criteria set by entities like CMS or private health plans, which could potentially lead to a delay or denial in device coverage and accessibility for patients.
For , thorough research on the subject device, including its users, competitive landscape, and regulatory history, is indispensable. By analyzing existing research literature, clinical studies, and the FDA’s 510(k) database, manufacturers can create a detailed comparative table to support their submission. This proactive approach, along with active engagement with the FDA, can help navigate the complexities of the , ultimately facilitating patient access to essential s.
Common Challenges and Best Practices
Navigating the for medical device approval can be intricate. A comprehensive understanding of both the device in question and is imperative. Applicants should delve into a thorough investigation of the device’s users, such as clinicians and patients, and meticulously review instructions for use, including all warnings and cautions. Alignment with Marketing teams can provide valuable insights into the competitive landscape, allowing for the identification of that share similar intended use and technological characteristics. This is integral to creating a robust submission document.
As noted by industry experts, the creation of a comparative table that outlines the similarities and differences between the subject device and the chosen predicate is a step that cannot be overlooked. To enhance this comparison, applicants should utilize resources such as research literature, , and FDA’s 510(k) database, which includes Summaries of Safety and Effectiveness (SSEs) for previously cleared devices.
The FDA, tasked with safeguarding public health, requires that submissions do not contain proprietary or confidential information that applicants do not wish to be made public. Therefore, it is the applicant’s responsibility to ensure that the submission is free of such sensitive data before electronic submission. In the event confidential information must be submitted, it should be done through a separate written and paper process as specified by the FDA.
Drawing from the experience of professionals in the field, like Chris, a biomedical engineer with over a decade of experience in medical device , it becomes clear that proactive communication with the FDA is crucial. Keeping an open dialogue throughout the 510(k) process can clarify questions and avoid potential pitfalls.
Statistics suggest that while the use of certain medical technologies is on the rise, the complexity of the 510(k) process remains a critical hurdle for many. With the goal of demonstrating to a legally marketed device, applicants must navigate this process with diligence and precision. By doing so, they can significantly enhance their likelihood of achieving .
Conclusion
The 510(k) submission process is crucial for introducing moderate-risk medical devices into the U.S. market. Thorough comparative analyses and evaluation of Summaries of Safety and Effectiveness (SSEs) are essential in light of recent scrutiny. Staying informed on FDA guidelines and developments is vital for regulatory compliance.
Understanding the device’s classification, intended use, and technological traits is crucial for a successful 510(k) submission. Collaboration with marketing teams and thorough investigation of the device and potential predicate devices are key. Adhering to FDA guidance and staying informed on FDA activities ensure a clear understanding of the regulatory environment.
Key components of a 510(k) submission include a cover letter, detailed device description, proposed labeling, performance data, and a comparison to the predicate device. Safeguarding sensitive information and following FDA guidelines for public comments are important considerations.
The step-by-step guide involves identifying a predicate device, determining the appropriate device classification, conducting comprehensive testing, preparing submission documentation, completing FDA forms accurately, and submitting the application to the FDA. Diligence in following these steps increases the likelihood of FDA clearance.
Comparing the new device to a predicate device is critical, as it demonstrates substantial equivalence. Adherence to FDA guidelines and staying updated on developments are essential. The substantial equivalence evaluation requires a meticulous comparison and stakeholder engagement through public comments and feedback.
In conclusion, the 510(k) submission process is a regulated pathway for introducing medical devices. Following best practices, engaging with the FDA, and staying informed on guidelines and developments enable manufacturers to navigate the process and work towards FDA clearance. This ensures the safety and effectiveness of medical devices for patients and healthcare providers.
Take the necessary steps to navigate the 510(k) submission process and achieve FDA clearance for your medical device. Contact us today to learn how we can assist you in following best practices and staying informed on guidelines and developments.
Frequently Asked Questions
What is the 510(k) submission process?
The 510(k) submission process is a regulatory mechanism by the FDA to oversee the introduction of moderate-risk medical devices into the U.S. market. It aims to affirm that a new device is ‘substantially equivalent’ to an existing device already cleared by the FDA, in terms of safety and effectiveness.
How are medical devices classified by the FDA?
The FDA categorizes devices into three classes based on the associated patient risk. Class I devices are low risk, Class II are moderate risk, and Class III are high risk.
What does ‘substantially equivalent’ mean in the 510(k) process?
‘Substantially equivalent’ means that a new medical device is as safe and effective as a predicate device, which is a similar device already legally marketed and cleared by the FDA.
What are the main regulatory pathways for medical devices?
The primary regulatory pathways are Premarket Notification (510(k)), Premarket Approval (PMA), and the De Novo process.
Can you legally market a medical device without FDA clearance, approval, or De Novo grant?
No, a device must be FDA Cleared, Approved, or Granted authorization through the De Novo process before it can be legally marketed in the U.S.
Why has the 510(k) process faced increased scrutiny?
The process has faced scrutiny due to concerns that not all devices undergo stringent clinical trials before approval, potentially compromising safety and effectiveness.
What is the importance of understanding the competitive landscape in the 510(k) process?
Understanding the competitive landscape helps in identifying potential predicate devices and ensuring that the new device is comparable in terms of intended use and technological characteristics.
What are the key components of a 510(k) submission?
A 510(k) submission must include a cover letter, a detailed device description, proposed labeling, performance data, and a comparison to the predicate device.
What should you consider when comparing your device to a predicate device?
You should conduct a thorough analysis of intended use, technological characteristics, and performance data to demonstrate that your device is substantially equivalent to the predicate device.
Is clinical data always required for the 510(k) process?
Not always. While non-clinical testing is often part of the review, clinical data may be required in certain scenarios to support claims of safety and effectiveness.
What is substantial equivalence evaluation in the 510(k) process?
It’s an assessment by the FDA to compare the new device with a predicate device in terms of intended use, technological attributes, and performance, ensuring that the new device does not raise new safety or effectiveness questions.
What is the FDA’s role in the review of 510(k) submissions?
The FDA reviews 510(k) submissions to ensure medical devices meet safety and effectiveness standards, comparing them against predicate devices.
How long does the FDA review process for a 510(k) submission take?
The review period varies but typically extends over several months. The timeline can fluctuate based on the complexity of the device and the thoroughness of the submission.
What happens after a device receives 510(k) clearance?
Post-clearance, other stakeholders like payors and healthcare providers assess the device to determine coverage and reimbursement, which can affect the device’s market accessibility.
What are common challenges in the 510(k) submission process?
Challenges include understanding FDA expectations, conducting a thorough investigation of the device, and ensuring the submission is well-documented and free of proprietary information.
What best practices should be followed during the 510(k) submission process?
Best practices include maintaining open communication with the FDA, utilizing resources like FDA guidance documents and databases, and ensuring accuracy and clarity in all documentation.
List of Sources
- What is the 510(k) Pathway?
- fda.gov (https://www.fda.gov/news-events/press-announcements/fda-clears-first-device-enable-automated-insulin-dosing-individuals-type-2-diabetes)
- fda.gov (https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/natures-pillows-inc-and-top-dog-direct-llc-676849-08072024)
- medtechintelligence.com (https://medtechintelligence.com/feature_article/fda-cleared-samd-by-the-numbers/)
- wcedmisten.fyi (https://wcedmisten.fyi/post/medical-device-analysis/)
- medtechintelligence.com (https://medtechintelligence.com/feature_article/510k-submission-planning/)
- rimsys.io (https://www.rimsys.io/blog/fda-listed-cleared-approved-granted)
- fda.gov (https://www.fda.gov/news-events/press-announcements/fda-roundup-november-21-2023)
- fda.gov (https://www.fda.gov/news-events/press-announcements/fda-roundup-october-20-2023)
- medtechintelligence.com (https://medtechintelligence.com/feature_article/510k-submission-planning/)
- rimsys.io (https://www.rimsys.io/blog/fda-listed-cleared-approved-granted)
- Eligibility Criteria for 510(k) Clearance
- ecfr.gov (https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-316/subpart-A)
- ecfr.gov (https://www.ecfr.gov/current/title-21/chapter-I/subchapter-E/part-514/subpart-B/section-514.115)
- fda.gov (https://www.fda.gov/news-events/press-announcements/fda-roundup-november-21-2023)
- fda.gov (https://www.fda.gov/news-events/press-announcements/fda-roundup-october-20-2023)
- fda.gov (https://www.fda.gov/news-events/press-announcements/fda-roundup-july-11-2023)
- fda.gov (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-recommendations-early-food-safety-evaluation-new-non-pesticidal-proteins-produced)
- medtechintelligence.com (https://medtechintelligence.com/feature_article/510k-submission-planning/)
- rimsys.io (https://www.rimsys.io/blog/fda-listed-cleared-approved-granted)
- medtechintelligence.com (https://medtechintelligence.com/feature_article/510k-submission-planning/)
- federalregister.gov (https://www.federalregister.gov/documents/2023/11/24/2023-25969/communications-from-firms-to-health-care-providers-regarding-scientific-information-on-unapproved)
- Key Components of a 510(k) Submission
- federalregister.gov (https://www.federalregister.gov/documents/2023/12/21/2023-28095/510k-third-party-review-program-and-third-party-emergency-use-authorization-eua-review-draft)
- federalregister.gov (https://www.federalregister.gov/documents/2023/09/29/2023-21405/electronic-submission-template-for-medical-device-de-novo-requests-draft-guidance-for-industry-and)
- federalregister.gov (https://www.federalregister.gov/documents/2024/07/12/2024-15337/dental-composite-resin-devices-and-dental-curing-lights-premarket-notification-510k-submissions)
- forum.effectivealtruism.org (https://forum.effectivealtruism.org/posts/oSAbWDuxmFZnsGEvx/case-study-safety-standards-on-california-utilities-to)
- medtechintelligence.com (https://medtechintelligence.com/feature_article/510k-submission-planning/)
- Step-by-Step Guide to Preparing a 510(k) Submission
- consensys.io (https://consensys.io/blog/consensys-repsonses-to-irs-proposed-rulemaking-for-digital-asset)
- medtechintelligence.com (https://medtechintelligence.com/feature_article/510k-submission-planning/)
- federalregister.gov (https://www.federalregister.gov/documents/2023/12/21/2023-28095/510k-third-party-review-program-and-third-party-emergency-use-authorization-eua-review-draft)
- federalregister.gov (https://www.federalregister.gov/documents/2023/09/15/2023-20014/annual-status-report-information-and-other-submissions-for-postmarketing-requirements-and)
- federalregister.gov (https://www.federalregister.gov/documents/2023/09/28/2023-21256/agency-information-collection-activities-proposed-collection-comment-request-application-for-food)
- fda.gov (https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)
- federalregister.gov (https://www.federalregister.gov/documents/2023/12/21/2023-28095/510k-third-party-review-program-and-third-party-emergency-use-authorization-eua-review-draft)
- Comparing Your Device to a Predicate Device
- fda.gov (https://www.fda.gov/news-events/press-announcements/fda-clears-first-device-enable-automated-insulin-dosing-individuals-type-2-diabetes)
- federalregister.gov (https://www.federalregister.gov/documents/2023/09/15/2023-20029/medical-devices-with-indications-associated-with-weight-loss-guidances-draft-guidances-for-industry)
- starfishmedical.com (https://starfishmedical.com/blog/using-the-fdas-best-practices-for-selecting-a-predicate-device/)
- thefdalawblog.com (https://www.thefdalawblog.com/2023/10/when-should-a-510k-include-clinical-data/?utm_source=rss&utm_medium=rss&utm_campaign=when-should-a-510k-include-clinical-data)
- fda.gov (https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)
- medtechintelligence.com (https://medtechintelligence.com/feature_article/510k-submission-planning/)
- ecfr.gov (https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-860/subpart-C)
- federalregister.gov (https://www.federalregister.gov/documents/2024/07/12/2024-15337/dental-composite-resin-devices-and-dental-curing-lights-premarket-notification-510k-submissions)
- fda.gov (https://www.fda.gov/news-events/press-announcements/fda-roundup-november-21-2023)
- fda.gov (https://www.fda.gov/news-events/press-announcements/fda-roundup-october-20-2023)
- fda.gov (https://www.fda.gov/news-events/press-announcements/fda-roundup-july-11-2023)
- medtechintelligence.com (https://medtechintelligence.com/feature_article/510k-submission-planning/)
- starfishmedical.com (https://starfishmedical.com/blog/using-the-fdas-best-practices-for-selecting-a-predicate-device/)
- Substantial Equivalence Evaluation
- fda.gov (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-recommendations-early-food-safety-evaluation-new-non-pesticidal-proteins-produced)
- fda.gov (https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)
- thefdalawblog.com (https://www.thefdalawblog.com/2023/10/when-should-a-510k-include-clinical-data/?utm_source=rss&utm_medium=rss&utm_campaign=when-should-a-510k-include-clinical-data)
- fda.gov (https://www.fda.gov/news-events/press-announcements/fda-roundup-november-21-2023)
- fda.gov (https://www.fda.gov/news-events/press-announcements/fda-roundup-october-20-2023)
- fda.gov (https://www.fda.gov/news-events/press-announcements/fda-roundup-july-11-2023)
- federalregister.gov (https://www.federalregister.gov/documents/2023/09/19/2023-20228/demonstrating-substantial-evidence-of-effectiveness-based-on-one-adequate-and-well-controlled)
- thefdalawblog.com (https://www.thefdalawblog.com/2023/10/long-awaited-guidance-on-fdama-115-confirmatory-evidence-finally-has-its-moment-to-be-crossed-off-the-fdas-guidance-to-do-list/?utm_source=rss&utm_medium=rss&utm_campaign=long-awaited-guidance-on-fdama-115-confirmatory-evidence-finally-has-its-moment-to-be-crossed-off-the-fdas-guidance-to-do-list)
- federalregister.gov (https://www.federalregister.gov/documents/2023/09/15/2023-20016/fostering-medical-device-improvement-food-and-drug-administration-activities-and-engagement-with-the)
- federalregister.gov (https://www.federalregister.gov/documents/2023/09/15/2023-20029/medical-devices-with-indications-associated-with-weight-loss-guidances-draft-guidances-for-industry)
- FDA Review Process and Timeline
- fda.gov (https://www.fda.gov/about-fda/cdrh-innovation/medical-device-coverage-initiatives-connecting-payors-payor-communication-task-force)
- medicaldevice-network.com (https://www.medicaldevice-network.com/sponsored/reducing-medical-device-approval-times-in-2023/)
- fda.gov (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-recommendations-early-food-safety-evaluation-new-non-pesticidal-proteins-produced)
- medtechintelligence.com (https://medtechintelligence.com/feature_article/510k-submission-planning/)
- fda.gov (https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)
- fda.gov (https://www.fda.gov/news-events/press-announcements/fda-roundup-november-21-2023)
- fda.gov (https://www.fda.gov/about-fda/cdrh-innovation/medical-device-coverage-initiatives-connecting-payors-payor-communication-task-force)
- rimsys.io (https://www.rimsys.io/blog/fda-listed-cleared-approved-granted)
- gao.gov (https://www.gao.gov/products/gao-24-106699?utm_medium=social&utm_source=twitter&utm_campaign=usgao)
- Common Challenges and Best Practices
- cdc.gov (https://www.cdc.gov/art/artdata/)
- accessdata.fda.gov (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm)
- navytimes.com (https://www.navytimes.com/news/your-navy/2023/11/22/mental-health-doesnt-cost-troops-security-clearances-data-shows/)
- greenlight.guru (https://www.greenlight.guru/blog/strategies-for-successful-pma-submissions-a-guide-for-clinical-teams)
- medtechintelligence.com (https://medtechintelligence.com/feature_article/510k-submission-planning/)
- federalregister.gov (https://www.federalregister.gov/documents/2023/12/21/2023-28095/510k-third-party-review-program-and-third-party-emergency-use-authorization-eua-review-draft)
- federalregister.gov (https://www.federalregister.gov/documents/2023/12/26/2023-28310/rare-diseases-considerations-for-the-development-of-drugs-and-biological-products-guidance-for)
- fda.gov (https://www.fda.gov/news-events/press-announcements/fda-roundup-november-21-2023)
- fda.gov (https://www.fda.gov/news-events/press-announcements/fda-roundup-september-13-2024)
- fda.gov (https://www.fda.gov/news-events/press-announcements/fda-proposes-rule-aimed-helping-ensure-safety-and-effectiveness-laboratory-developed-tests)
